An observational study in Age-related Cognitive Decline, sponsored by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace. Terminated at 1 site in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace · Observational
The purpose of this prospective monocenter observational study is to assess the impact of the first introduction of formal home help (personalized autonomy allowance for seniors) on the quality of life of home caregivers of elderly patients with neurocognitive impairment.
An aging population is leading to an increase in neurodegenerative disorders that are responsible for loss of autonomy. In order to keep patients with neurocognitive impairment at home, the availability of home caregivers is essential. The neurocognitive deterioration of elderly patients is a significant burden for home caregivers and can affect their quality of life. The implementation of formal home help (personalized autonomy allowance for seniors) can relieve home caregivers and improve their quality of life.
Conduct of research:
Elderly patients followed in the geriatric department of the Mulhouse French hospital, and for whom a formal home help (personalized autonomy allowance for seniors) is initiated will be recruited. The evolution of home caregiver's quality of life, burden and vulnerability, will be assessed during three months.
3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,099 are open to participants now.
This study's enrollment of 12 is below the median of 150 across 950 observational studies indexed under Cognitive Dysfunction.
Browse Cognitive Dysfunction studies →Groupe Hospitalier de la Region de Mulhouse et Sud Alsace is the lead sponsor of 27 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Elderly people with neurocognitive disorders benefiting from a home support program (personalized autonomy allowance for seniors program).
Exclusion criteria:
Setting up of a formal home help
Caregiver quality of life
Variation of caregiver quality of life between inclusion and 90 days. Quality of life is assessed with the PIXEL study evaluation scale. This is a 20-item scale, subdivided in four domains: behavioral capacities to face difficulties generated by the patient, relation with the environment, psychological perception of the situation, perception of a possible distress. Score ranges from 0 to 100 points (5 points for each item).
Time frame: 90 days
Caregiver vulnerability
Variation of caregiver vulnerability between inclusion and 90 days. Vulnerability is assessed through another PIXEL study 20-item evaluation scale. Score ranges from 0 to 100 points.
Time frame: 90 days
Caregiver burden
Variation of caregiver burden between inclusion and 90 days. Burden is assessed with the 7-item mini-Zarit scale. Score ranges from 0 to 7.
Time frame: 90 days
Caregiver quality of life according to the type of formal home care
Variation of caregiver quality of life between inclusion and 90 days. Quality of life is assessed with the PIXEL study evaluation scale.
Time frame: 90 days
Caregiver vulnerability according to the type of formal home care
Vulnerability is assessed through another PIXEL study 20-item evaluation scale.
Time frame: 90 days
Caregiver burden according to the type of formal home care
Variation of caregiver burden between inclusion and 90 days. Burden is assessed with the 7-item mini-Zarit scale. Score ranges from 0 to 7.
Time frame: 90 days
Variation of quality of life score according to each domain
Evolution of quality of life according to each domain of the PIXEL study evaluation scale.
Time frame: 90 days
Description of the aids set up within the framework of the personalized autonomy allowance for seniors program.
Formal home help can include several home services: meal delivery, domestic help, home care nurse, etc.
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace